Today, the majority of drugs and pharmaceuticals on the market that treat human disease are designed to target a specific protein. But University of North Carolina at Chapel Hill startup Ribometrix has a very different, revolutionary approach to new drug discovery that’s proving to be a breakthrough in the industry.
Ribometrix’s novel approach has the potential to improve millions of lives by offering new treatments for a range of diseases, ranging from cancer, neurological disorders, immunological diseases, and rare diseases such as Huntington’s Disease.
“What’s really exciting is that our specialized technologies give us the ability to go after a whole series of targets that were once considered un-targetable,” says Katie Warner, co-founder and director of research at Ribometrix. “All proteins – including those currently viewed as undruggable – are made from a messenger RNA. The Ribometrix platform allows us to potentially target any of these proteins by targeting those RNAs with small molecules. This is not a small idea, and has the potential to be a big game changer for what drug discovery can do.”
| UNC-CH